Neola Medical AB (publ) announced that it has been granted a U.S. patent covering the disposable probes used in its medical device Neola®, a system designed for continuous lung monitoring of preterm infants. The newly approved patent strengthens the company’s intellectual property portfolio in its most critical commercial market.

Neola® uses advanced light and detector probes to continuously monitor both lungs of preterm newborns. The system requires two probe sets, which are replaced daily. As a result, the disposable components form a key part of Neola Medical’s scalable and recurring revenue model. The U.S. patent adds protection in a major target market and complements the company’s already granted European patent, with a similar application currently under review in China.

CEO Hanna Sjöström emphasized the importance of the patent to Neola Medical’s long-term business strategy.
“Securing patent protection in the U.S. strengthens our competitive position in our most important target market and protects our unique optical design. These disposables are central to our future business model, where recurring revenues from daily probe replacements are expected to provide significant leverage,” she said.

About the Patent

The granted patent is part of the family titled “A light diffuser and a method for assembling the same.” It protects Neola Medical’s specialized innovation for creating a uniform, diffuse light distribution from the dermal emitter probe.

This optical design is crucial for the Neola® system, enabling safe, non-invasive, and continuous lung monitoring using optical spectroscopy — a breakthrough approach aimed at improving outcomes for vulnerable preterm infants.